Your session is about to expire
← Back to Search
KFA115 + Tislelizumab for Advanced Cancers
Study Summary
This trial tests the safety and side effects of two drugs for advanced cancers, to find the safest and most effective dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never had lung inflammation or similar lung issues that needed strong steroids.I have melanoma that worsened after anti-PD(L)1 therapy and, if BRAF V600 mutant, was also treated with a BRAF inhibitor.My lung cancer responded to previous immunotherapy for at least 4 months and I've had platinum-based chemotherapy.I can stop taking medications that affect my heart's rhythm for the study.I am willing and able to have a biopsy as per my hospital's rules.I have high-grade serous ovarian cancer, haven't had anti-PD(L)1 therapy, and had one treatment after becoming platinum-resistant.I have a specific type of advanced cancer and haven't received anti-PD(L)1 therapy.I weigh more than 36 kg.I have nerve pain or tingling that affects my daily activities.I have clear cell renal cancer, treated with anti-PD(L)1 and VEGF therapies, and my disease has progressed.I stopped anti-PD-(L)1 therapy because of its side effects.My cancer is advanced nasopharyngeal, not treated with anti-PD(L)1 before.I have heart problems that affect my daily activities.I have an autoimmune disease but it's under control or not severe.
- Group 1: KFA115 + pembrolizumab
- Group 2: Single-agent KFA115
- Group 3: KFA115 run-in (1 cycle) + pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential adverse effects could arise from single-agent KFA115?
"Due to the limited data available from Phase 1 clinical trials, Single-agent KFA115 garnered a safety rating of 1 on our team's scale."
Are there still vacancies available to participate in this experiment?
"Clinicaltrials.gov has confirmed that this medical trail is actively seeking patients, the listing having been created on October 26th 2022 and last updated on May 8th of 2023."
Is this medical study being conducted in various parts of the United States?
"At present, 5 centres are actively enrolling participants for this trial; with locations in Toronto, Shatin New Territories and Shatin. To reduce the time spent commuting if you become part of the study it is advised to choose a centre closest to your residence."
How many participants are eligible to partake in this clinical trial?
"Affirmative. According to clinicaltrials.gov, the study is still enlisting participants and commenced on October 26th 2022. It was last modified on May 8th 2023 with a total of 220 patients being accepted from 5 medical sites."
What results are researchers hoping to achieve through this clinical trial?
"As specified by the trial sponsor, Novartis Pharmaceuticals, primary outcomes will be ascertained over a period of 28 days. Specifically, they are gaugeing incidents and levels dose limiting toxicities (DLTs) during their evaluation phase alongside immunogenicity when tislelizumab is administered in combination with KFA115. Secondary objectives encompass determining those that develop anti-drug antibodies (ADA), duration of response per RECIST v1.1 definition from first documented response to first observed progression or death due to underlying cancer, and best overall recordable responses according to RECIST v1.1 specifications."
Share this study with friends
Copy Link
Messenger